Slide 1: Business Overview for Individual Investors
Business Overview for Individual Investors Sysmex Corporation （TSE Prime: 6869）
Slide 2: Index
Index 1 Sysmex’s Present What sort of company is Sysmex? 2 Sysmex’s Future Toward Further Growth 3 Financial Forecast, Shareholder Returns 2
Slide 3: Sysmex's Present: What sort of company is Sysmex?
1 Sysmex’s Present What sort of company is Sysmex?
Slide 4: Sysmex's Profile
Sysmex’s Profile No. 1 share Net sales Grew by approx. ¥100 ¥508.6 billion Fiscal year ended March 31, 2025 600 6,000 of the global market in billion in two years (Billions of yen) the fields of Hematology ¥410.5 billion Fiscal year ended March 31, 2023 5,000 500 Hemostasis Urinalysis 400 4,00
Slide 5: Philosophy at Founding: Three Aspects of Confidence
Philosophy at Founding: “Three Aspects of Confidence” “We contribute to resolving social issues and enrich our own lives by providing the products we produce.” To realize this… Founder Taro Nakatani Total confidence Total confidence Total confidence of of of Customers Business Employees Partners “Th
Slide 6: Corporate Philosophy
Corporate Philosophy Sysmex Way Mission Shaping the advancement of healthcare. Value We will continue to create unique and innovative values, and ensure anshin for individuals in society. Mind With passion and flexibility, we demonstrate our individual competence and unsurpassed teamwork. Shared Val
Slide 7: Where Sysmex Products Are Used
Where Sysmex Products Are Used Main user locations Market scale Scale of the global IVD market CAGR: Approx. 4% Approx. Hospitals, health Clinics ¥ 12.2 trillion screening centers Approx. 80.0 billion USD 1USD =¥152.6 Commercial Note: Sysmex has compiled data on market scale and growth rates bas
Slide 8: Sysmex Is an In Vitro Diagnostic Company
Sysmex Is an In Vitro (Blood, Urine) Diagnostic Company Samples（blood,urine） collected at hospitals and health screening centers is analyzed with Sysmex instrument. Blood Measurement, Diagnosis sampling analysis Blood collection room Laboratory Examination room 8
Slide 9: In Vitro Diagnostics Supporting Healthcare
In Vitro Diagnostics Supporting Healthcare Testing underpins many healthcare decisions. Sysmex operates in the area of testing called in vitro diagnosis (IVD), which involves measuring blood, urine, and other samples. in vitro diagnosis Hematology Hemostasis Anemia, leukemia, Hemophilia, myocardial
Slide 10: Places Where Sysmex Products Excel (Image)
Places Where Sysmex Products Excel (Image) Laboratory technologists use various instruments to analyze and measure blood and other samples. Clinical testing laboratory Hematology Urinalysis Blood collection room (Blood collection tables) Immunochemistry Hemostasis 10
Slide 11: About Hematology
About Hematology Sysmex’s greatest strength is in Hematology, screening tests that are consistent around the world. Testing determines the number of and abnormalities in red and white blood cells and platelets. The red blood cells, white blood cells, and platelets that circulate throughout the bod
Slide 12: Products Used in Hematology
Products Used in Hematology Testing uses a combination of specialized instruments and reagents. Instruments Reagents For large hospitals and commercial labs For medium-sized hospitals For clinics 12
Slide 13: Business Model
Business Model Ongoing sales from reagents, services, and support After selling an instrument, we generate steady revenue over the course of five Services and support Approx. 70% of to seven years from the sale of reagents, services, and support. sales from Sales per customer reagents, services, a
Slide 14: No. 1 Share of the Global Market in the Field of Hematology
No. 1 Share of the Global Market in the Field of Hematology Contributing to the health of people around the world through hematology Sales/Services bases Reagent production sites Device production sites 63 sites in 45 countries 14 sites in 10countries 8 sites, mainly in Japan Responding to regional-
Slide 15: What Customers Expect
What Customers Expect Sysmex’s direct customers Healthy and pre-symptomatic people, patients Doctors Laboratories Receive appropriate healthcare at Provide appropriate, high-quality Provide doctors with accurate test the necessary times and locations diagnoses and treatment to results and diagnostic
Slide 16: Products (1)
Products（1） Our products offer high quality and high durability The fusion of diverse Development ability to meet technologies expectations Reporting of results Measurement of minute samples Software Multiparameter Fluids Mechanics Instruments analysis Electronics High repeatability Optics Cell meas
Slide 17: Products (2)
Products (2) We strive to provide products and services that exceed customers’ expectations. 1960s 1980～90s Growing health-related demand, improvements in testing efficiency spurred by economic growth Ensuring the safety of technologists Increase in the number of tests Automation of testing/ promoti
Slide 18: Products (3)
Products (3) We strive to provide products and services that exceed customers’ expectations. 2000s 2020s Utilization of IT to achieve Further gains in efficiency and eco- improvements in testing quality and friendliness efficiency Fully automated systems IT adapted products and services Development
Slide 19: Creating New Value in Hematology
Creating New Value in Hematology Achieving full automation through the touch-free concept automated hematology analyzers XR-9000 Automatic Automatic Sample Blood Smear Sample Automatic image sample Measurement quality shutdown storage analysis preparation sorting startup control (1) Automation of qu
Slide 20: Service Structure
Service Structure Inventions not to stop testing at medical institutions If testing is interrupted Using networks to prevent breakdowns from occurring Laboratories Doctors Test results cannot Accurate diagnosis and be reported to the treatment based on test doctor results is not possible Real-ti
Slide 21: Scientific Support
Scientific Support By providing scientific information and support, we help improve the quality of testing. Holding scientific seminars at locations around the world We organize seminars and provid academic materials on the latest information on medical care and Wide range of testing with the cooper
Slide 22: Expanding the Number of Regions Where We Provide Direct Sales, Services, and Support
Expanding the Number of Regions Where We Provide Direct Sales, Services, and Support Direct sales helps us ascertain customer needs and find new growth opportunities. Until the 1990s 2000s 2020s Efficient expansion of direct sales No. 1 share of the global Transition to direct sales areas by acquiri
Slide 23: Creating Social Value
Creating Social Value Contributing to society through our products and services Initiatives to improve accessibility to healthcare Contributing to fair sports management Contributing to the early diagnosis and Helping to improve the quality of doping tests treatment of malaria We have developed
Slide 24: The No. 1 Share of the Global Market in the Hematology Field
The No. 1 Share of the Global Market in the Hematology Field We have been striving to meet and exceed the expectations of our customers all over the world, thereby establishing an overwhelming position. Products Direct sales and services High performance, high quality, (1) Uninterrupted testing Conf
Slide 25: Sysmex's Future: Toward Further Growth
2 Sysmex’s Future Toward Further Growth
Slide 26: Accelerating Evolution of Health Tech
Accelerating Evolution of Health Tech Changing healthcare Acceleration of New treatment awareness digital technologies modalities Increase in new entrants Expansion of digital healthcare Response to increasingly Response to increasingly Development of products and services sophisticated treatment di
Slide 27: Sysmex's New Long-Term Corporate Strategy
Sysmex’s New Long-Term Corporate Strategy “Together for a better healthcare journey” Expansion of testing Increase in the type of situations that require testing Creation of new value New initiatives Robotic-assisted surgery system Regenerative and cellular medicine 27
Slide 28: Growth Strategy in Sysmex
Growth Strategy in Sysmex We are continuously evolving to help people around the world lead healthy and fulfilling lives. Over 1,000 growth strategy I. Reinforcement of (billions of yen) Existing Businesses 508.6 535.0 II. Business Expansion in Emerging Countries III. Expansion of new businesses 202
Slide 29: Initiatives for the Reinforcement of Existing Businesses
Initiatives for the Reinforcement of Existing Businesses Expansion in the Hemostasis and Other Fields
Slide 30: Reinforcement of Existing Businesses (1): Strategy in the Hemostasis Field
Reinforcement of Existing Businesses(1): Strategy in the Hemostasis Field Global OEM agreement with Siemens in hemostasis field (effective April 1, 2024) Approximately doubling the target market ■Sales in the Hemostasis Field (Billions of yen) (Results and Forecasts) Target market to date Market 市場規
Slide 31: Reinforcement of Existing Businesses (1): Strategy in the Hemostasis Field
Reinforcement of Existing Businesses(1): Strategy in the Hemostasis Field Global sales network and abundant Strength in the hematology business due to high levels of human resources customer satisfaction and a No. 1 market share in Europe and the Americas Leverage channels in the Maximize synergy wi
Slide 32: Reinforcement of Existing Businesses (2): Expansion in the Immunochemistry Field
Reinforcement of Existing Businesses (2)： Expansion in the Immunochemistry Field Aiming to expand blood-based testing for Alzheimer’s disease Number of dementia patients continues Proposing new testing methods to increase*¹ Currently: More than 55 million people Low cost Low physical burden (sim
Slide 33: Initiatives for emerging market strategies
Initiatives for emerging market strategies Growth in India, Brazil, and Other Countries
Slide 34: Growth potential in emerging markets
Growth potential in emerging markets Improving the quality of healthcare in emerging markets presents a major growth opportunity. The potential healthcare market Source：World Health Organization 2021 34
Slide 35: Emerging Market Strategies
Emerging Market Strategies Proactive initiatives in markets that are expected to grow substantially India Sales in India (Billions of yen) Expanding production base Planning to start manufacturing in 11.5 the fiscal year ending March 31, 7.2 9.2 2025 2026 Launch sales of products for the 2024 20
Slide 36: Initiatives for the Expansion of New Businesses
Initiatives for the Expansion of New Businesses Medical Robotics and Other Businesses
Slide 37: Expansion of New Businesses
Expansion of New Businesses Medical robotics business Regenerative and cellular medicine Platelet derived from iPS cells Robotic-assisted surgery system Digital medicine Home healthcare support system 37
Slide 38: Expansion of New Business: Medical Robotics Business
Expansion of New Business : Medical Robotics Business Surgical support robots moving healthcare to a new stage Healthcare needs Taking on challenges in new domains Reduced burden on patients, contributing to earlier return to daily life Enabling highly precise surgery through robotic-assisted pr
Slide 39: Expansion of New Business: Medical Robotics Business
Expansion of New Business：Medical Robotics Business We made steady progress in overseas market deployment, buoyed by a favorable business environment. Progress in the fiscal year ended March 31, 2025 global rollout plan ■ hinotoriTM units installed globally to date +34 this fiscal year ■Results by q
Slide 40: Financial Forecast, Shareholder Returns
3 Financial Forecast , Shareholder Returns
Slide 41: Results for FY Ended March 2025 and Forecast for FY Ending March 2026
Results for the Fiscal Year Ended March 31, 2025 and Financial Forecast for the Fiscal Year Ending March 31, 2026 (Billions of yen) Fiscal year ended March 31, 2025 Financial forecast for the fiscal year ending March 31, 2026 535.0 508.6 YoY (Previous YoY 461.5 Results Ratio period = Forecast Ratio
Slide 42: New Dividend Policy and Dividend Forecast
New Dividend Policy and Dividend Forecast for the Fiscal Year Ending March 31, 2026 In terms of returns to shareholders, we intend to provide a stable dividend on a continuous basis and aim for a consolidated payout ratio of 40% , adopt progressive dividend approach under our basic policy of sharing
Slide 43: Together for a better healthcare journey
Together for a better healthcare journey